Ziextenzo

It took a 3-year struggle, but Novartis finally gets a green light on their copycat to Amgen's big blockbuster
Endpoints
Tue, 11/5/19 - 10:23 am
Novartis
FDA
Amgen
Neulasta
biosimilars
Ziextenzo
cancer